Xtant Medical CEO Dan Goldberger announces resignation
Jan 23, 2017 12:30 pm UTC| Business
BELGRADE, Mont., Jan. 23, 2017 -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced...
Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
Jan 23, 2017 12:30 pm UTC| Business
Plans to Apply for Orphan Drug Designation RADNOR, Pa., Jan. 23, 2017 -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced positive preliminary data from the initial CDKL5 patients enrolled in its ongoing...
EDAP to Exclusively Distribute LABORIE’s Medical Measurement Systems Urodynamic Products in Japan
Jan 23, 2017 12:30 pm UTC| Business
LYON, France, Jan. 23, 2017 -- EDAP TMS SA (NASDAQ:EDAP), the global leader in therapeutic ultrasound, announced today that it has signed an exclusive agreement with the Canadian company LABORIE to distribute their...
Jan 23, 2017 12:20 pm UTC| Business
Unaudited Preliminary Financial and Operating Results Endeavour Posts Record Performance in Q4, Meets 2016 Guidance and Expects Further Production Growth and AISC Reduction in 2017 View News Release in PDF...
ANSYS to Release Fourth Quarter and FY 2016 Earnings on February 23, 2017
Jan 23, 2017 12:09 pm UTC| Business
PITTSBURGH, Jan. 23, 2017 -- ANSYS, Inc. (NASDAQ:ANSS) announced today that the Company expects to release its fourth quarter and FY 2016 earnings on Thursday, February 23, 2017. The Company will hold a conference call...
Matinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
Jan 23, 2017 12:05 pm UTC| Business
BEDMINSTER, N.J., Jan. 23, 2017 -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that...
Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division
Jan 23, 2017 12:01 pm UTC| Business
Uppsala, January 23, 2017 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced that it plans to move all of the Company’s veterinary...